The expectation is that tivo's S/E profile is better than Nexavar, isn't it?
Yes, it appears to be substantially better based on what they said in the call (consonant with their Phase II safety data, but of course we still need to see the detailed data).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.